azelnidipine has been researched along with Alloxan Diabetes in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hosoya, M; Ohashi, J; Sawada, A; Shimokawa, H; Takaki, A | 1 |
| Kain, V; Kumar, S; Puranik, AS; Sitasawad, SL | 1 |
| Amirghofran, Z; Bagheri, M; Jahromi, BM; Mirkhani, H; Noorafshan, A; Solhjou, Z; Zamani, A | 1 |
| Kain, V; Kumar, S; Sitasawad, SL | 1 |
| Fukumoto, Y; Hosoya, M; Nakajima, S; Noda, K; Ohashi, J; Shimokawa, H | 1 |
| Kurabayashi, M; Nakamura, T; Saito, T; Saito, Y | 1 |
6 other study(ies) available for azelnidipine and Alloxan Diabetes
| Article | Year |
|---|---|
Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Azetidinecarboxylic Acid; Biological Factors; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Signal Transduction; Streptozocin; Tetrazoles; Vasodilation | 2010 |
Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage.
Topics: Animals; Azetidinecarboxylic Acid; Biomarkers; Blood Glucose; Calcium Channel Blockers; Catalase; Cytokines; Diabetes Mellitus, Experimental; Dihydropyridines; Glutathione; Heart Diseases; Homocysteine; Inflammation Mediators; Insulin; Lipid Peroxidation; Lipids; Liver; Male; Myocardium; Oxidative Stress; Protein Carbonylation; Rats; Rats, Wistar; Superoxide Dismutase | 2010 |
Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Male; Nitric Oxide; Nitrites; Rats; Skin; Streptozocin; Wound Healing | 2011 |
Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Azetidinecarboxylic Acid; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dihydropyridines; Male; Myocardial Contraction; Myocardium; Oxidative Stress; Phosphoproteins; Rats; Rats, Wistar; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Superoxides; Time Factors; Troponin I; Ventricular Dysfunction, Left; Ventricular Function, Left | 2011 |
Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Azetidinecarboxylic Acid; Azo Compounds; Blood Pressure; Body Weight; Calcium Channel Blockers; Coronary Vessels; Diabetes Mellitus, Experimental; Dihydropyridines; Drug Therapy, Combination; Imidazoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Models, Biological; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Systole; Tetrazoles | 2012 |
Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.
Topics: Animals; Aorta, Thoracic; Azetidinecarboxylic Acid; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Down-Regulation; Heart; Hypertension; Kidney Cortex; Male; Myocardium; Organ Size; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Strains; Receptors, Mineralocorticoid; Renin-Angiotensin System; RNA, Messenger | 2006 |